United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by New England Research & Management Inc.

New England Research & Management Inc. trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 26.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 5,640 shares of the biotechnology company’s stock after selling 2,080 shares during the period. United Therapeutics makes up 1.0% of New England Research & Management Inc.’s portfolio, making the stock its 28th biggest holding. New England Research & Management Inc.’s holdings in United Therapeutics were worth $1,990,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Milestone Asset Management LLC boosted its stake in United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 1,037 shares during the last quarter. Pacer Advisors Inc. raised its holdings in shares of United Therapeutics by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 597,634 shares of the biotechnology company’s stock worth $210,869,000 after purchasing an additional 30,931 shares during the period. Center For Asset Management LLC raised its holdings in shares of United Therapeutics by 4.5% during the 4th quarter. Center For Asset Management LLC now owns 1,686 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 73 shares during the period. KBC Group NV raised its holdings in shares of United Therapeutics by 6.2% during the 4th quarter. KBC Group NV now owns 123,055 shares of the biotechnology company’s stock valued at $43,418,000 after buying an additional 7,169 shares during the period. Finally, Blue Trust Inc. raised its holdings in shares of United Therapeutics by 24.2% during the 4th quarter. Blue Trust Inc. now owns 1,745 shares of the biotechnology company’s stock valued at $625,000 after buying an additional 340 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Trading Up 0.5 %

Shares of UTHR opened at $372.75 on Thursday. The firm has a market cap of $16.64 billion, a price-to-earnings ratio of 16.37, a PEG ratio of 0.95 and a beta of 0.57. The stock has a 50 day moving average of $365.77 and a 200-day moving average of $356.81. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s revenue was up 22.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.38 EPS. On average, sell-side analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. LADENBURG THALM/SH SH raised their target price on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. TD Cowen lifted their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, Argus lifted their price objective on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $378.36.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 510 shares of United Therapeutics stock in a transaction on Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 12.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Nilda Mesa sold 255 shares of United Therapeutics stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,048 shares of company stock worth $56,142,199. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.